Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Change in Acquisitions & Divestments (2018 - 2022)

Spero Therapeutics (SPRO) has disclosed Change in Acquisitions & Divestments for 5 consecutive years, with $49.9 million as the latest value for Q2 2022.

  • For the quarter ending Q2 2022, Change in Acquisitions & Divestments rose 143.27% year-over-year to $49.9 million, compared with a TTM value of $49.9 million through Mar 2023, down 11.66%, and an annual FY2022 reading of $60.8 million, up 17.9% over the prior year.
  • Change in Acquisitions & Divestments was $49.9 million for Q2 2022 at Spero Therapeutics, up from $10.9 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $50.6 million in Q1 2019 and bottomed at $2.0 million in Q4 2020.
  • Average Change in Acquisitions & Divestments over 5 years is $20.7 million, with a median of $18.3 million recorded in 2020.
  • The sharpest move saw Change in Acquisitions & Divestments crashed 85.61% in 2020, then skyrocketed 351.2% in 2021.
  • Year by year, Change in Acquisitions & Divestments stood at $35.5 million in 2018, then crashed by 76.03% to $8.5 million in 2019, then tumbled by 76.47% to $2.0 million in 2020, then soared by 250.0% to $7.0 million in 2021, then surged by 612.44% to $49.9 million in 2022.
  • Business Quant data shows Change in Acquisitions & Divestments for SPRO at $49.9 million in Q2 2022, $10.9 million in Q1 2022, and $7.0 million in Q4 2021.